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Abstract
Identifying the genes that influence levels of pro-inflammatory molecules can help to elucidate the mechanisms underlying
this process. We first conducted a two-stage genome-wide association scan (GWAS) for the key inflammatory biomarkers
Interleukin-6 (IL-6), the general measure of inflammation erythrocyte sedimentation rate (ESR), monocyte chemotactic
protein-1 (MCP-1), and high-sensitivity C-reactive protein (hsCRP) in a large cohort of individuals from the founder
population of Sardinia. By analysing 731,213 autosomal or X chromosome SNPs and an additional ,1.9 million imputed
variants in 4,694 individuals, we identified several SNPs associated with the selected quantitative trait loci (QTLs) and
replicated all the top signals in an independent sample of 1,392 individuals from the same population. Next, to increase
power to detect and resolve associations, we further genotyped the whole cohort (6,145 individuals) for 293,875 variants
included on the ImmunoChip and MetaboChip custom arrays. Overall, our combined approach led to the identification of 9
genome-wide significant novel independent signals—5 of which were identified only with the custom arrays—and
provided confirmatory evidence for an additional 7. Novel signals include: for IL-6, in the ABO gene (rs657152,
p=2.13610
229); for ESR, at the HBB (rs4910472, p=2.31610
211) and UCN119B/SPPL3 (rs11829037, p=8.91610
210) loci; for
MCP-1, near its receptor CCR2 (rs17141006, p=7.53610
213) and in CADM3 (rs3026968, p=7.63610
213); for hsCRP, within
the CRP gene (rs3093077, p=5.73610
221), near DARC (rs3845624, p=1.43610
210), UNC119B/SPPL3 (rs11829037,
p=1.50610
214), and ICOSLG/AIRE (rs113459440, p=1.54610
208) loci. Confirmatory evidence was found for IL-6 in the IL-
6R gene (rs4129267); for ESR at CR1 (rs12567990) and TMEM57 (rs10903129); for MCP-1 at DARC (rs12075); and for hsCRP at
CRP (rs1205), HNF1A (rs225918), and APOC-I (rs4420638). Our results improve the current knowledge of genetic variants
underlying inflammation and provide novel clues for the understanding of the molecular mechanisms regulating this
complex process.
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Introduction
Inflammation is a critical response to pathogens and injuries. Its
control entails a coordinated cascade of biological events regulated
by specific cells and molecular signals, in a complex process that is
only partially understood. In this context, genetics can provide
important clues, given that population studies indicate that about
half of the inter-individual variability in biomarkers of inflamma-
tion is genetically determined and considering the achievements of
GWA scans (GWAS) in complex trait analysis during the last few
PLoS Genetics | www.plosgenetics.org 1 January 2012 | Volume 8 | Issue 1 | e1002480years [1–6]. To date, however, the genetic variants involved in the
control of inflammation are still largely unidentified.
The relevance for clarifying the genetic bases of inflammation
and understanding their mechanistic consequences is multi-fold.
The immediate importance regards a better understanding of the
regulation of the components of inflammation itself. Furthermore,
recent population genetic studies have suggested that natural
selection has shaped the evolution of innate immunity, with a
specific pressure on those inflammatory genes that play a pivotal
role in host-pathogen interactions [7,8]. In addition, the
inflammatory response can also influence in a positive or negative
way the risk for several complex non-infectious diseases, as
highlighted by recent studies on cardiopathologies and metastatic
processes [9,10]; knowing the variants involved in the process can
thus have implications in different clinical settings.
To identify the genetic variants explaining the inter-individual
variability in biomarkers of inflammation, we conducted a GWAS
for the levels of the key inflammatory biomarkers interleukin-6 (IL-
6), erythrocyte sedimentation rate (ESR), monocyte chemotactic
protein-1 (MCP-1) and the C-reactive protein using the high-
sensitivity assay (hsCRP) in a large cohort of Sardinian individuals
from the SardiNIA study [11]. These markers represent different
pathways and stages in the inflammatory cascade and their serum
levels are used for the diagnosis and management of different
inflammatory conditions during both the acute and chronic
immune response.
Results
We initially assessed 731,213 autosomal or X chromosome
SNPs and imputed further ,1.9 million variants in 4,694
individuals (Step 1) and then replicated the top signals in an
additional 1,392 individuals (Step 2). To increase the detection
power and provide useful information for the fine mapping stage
we have also evaluated the whole cohort of 6,145 individuals with
the ImmunoChip (151,085 variants) [12] and the MetaboChip
(142,790 variants, of which 9,920 overlapped with ImmunoChip)
[13] (Step 3). Overall we detected variants significantly associated
with each of the traits assessed. The salient results are reported
below.
Step 1: Genome-Wide Association Scan
We identified several SNPs above the standard genome-wide
significant threshold (5610
208) in the SardiNIA discovery cohort
(Table 1, Table S1 and Figure S1). The region surrounding each
of these SNPs was studied in more detail as the respective traits
were analyzed (see below).
IL-6
For IL-6, SNPs with p-values,5610
28 were all located in the
ABO (a-1-3-N-acetylgalactosaminyltransferase) locus on chromosome
9q34.1-q34.2 (Table S1), encoding the Histo-blood group ABO
system transferase, with the strongest signal at rs643434 in intron 1
of the gene (p=2.69610
221, 0.69 pg/ml average increase per G
allele) (Table 1). This SNP is in strong linkage disequilibrium (LD)
with another associated variant, rs687289, which tags the O allele
of the ABO locus (r
2=0.931 in HapMap CEU).
ESR
For ESR, we identified several associated SNPs on chromosome
1q32, all within the CR1 (complement component (3b/4b) receptor 1)
gene, a member of the receptors of the complement activation
family, recently shown associated with ESR (Table S1) [14]. The
strongest signal was observed at rs12034598 in intron 22 of CR1,
with a p-value of 9.31610
211 (1.024 mm/h average increase per
G allele) (Table 1). This SNP is in strong LD with other associated
variants including rs2274567 (r
2=1), a non-synonymous SNP in
exon 22 that causes a His1208Arg substitution predicted as
potentially damaging by PolyPhen and affecting expression levels
of CR1 on the erythrocytes (Table S1) [15,16]. In the genomic
region covered by CR1 several copy number variations (CNVs)
have been identified. However, none of the 38 SNPs in this region
with p-value,5610
208 (Table S1) tags the CNVs reported in a
previous study [17,18]. In addition, CNVs analysis with PennCNV
[19] in individuals genotyped with the Affymetrix 6.0 microarray
did not show presence of CNVs in our samples (unpublished data).
Still, we could not exclude the presence of population-specific
CNVs or common CNVs not directly interrogated by the
Affymetrix probes.
We also found a locus suggestively associated with ESR on
chromosomes 11p15 in the b-globin locus control region (LCR), which
coordinates the expression of the globin genes (Table S1). The top
signal was at marker rs4910742 (p=6.34610
208) (Table 1), which
is a surrogate for the b
039 mutation carried by a large portion (11–
13%) of the Sardinians and able to influence the levels of several
blood indices, including number of RBCs [20], a parameter that
has an inverse relationship with ESR. Accordingly, when we
repeated the association analysis including in the model b-
Thalassemia (b-Thal) carrier status as a covariate, the association at
rs4910742 disappeared (p=0.54 in SardiNIA).
MCP-1
The GWAS results for MCP-1 levels revealed strong association
signals on chromosome 1q22-q23 (Table S1). The associated
region encompassed ,500 kb and contained several genes, with
the top signal detected in the DARC (Duffy blood group chemokine
receptor) gene at marker rs12075 (p=1.68610
230, 36.78 pg/ml
average increase per A allele), as also shown in a recent meta-
analysis (Table 1) [21]. The association curve encompasses several
other genes, including the CADM3 (cell adhesion molecule 3) locus
upstream of DARC, as well as in the FCER1A (Fc fragment of IgE, high
Author Summary
Inflammation is a protective response of our organism to
harmful stimuli—such as germs, damaged cells, or
irritants—and to initiate the healing process. It has also
been implicated, with both protective and predisposing
effects, in a number of different diseases; but many
important details of this complex phenomenon are still
unknown. Identifying the genes that influence levels of
pro-inflammatory molecules can help to elucidate the
factors and mechanisms underlying inflammation and
their consequence on health. Genome-wide association
scans (GWAS) have proved successful in revealing robust
associations in both common diseases and quantitative
traits. Here, we thus performed a multistage GWAS in a
large cohort of individuals from Sardinia to examine the
role of common genetic variants on the key inflammatory
biomarkers Interleukin-6, erythrocyte sedimentation rate,
monocyte chemotactic protein-1, and high-sensitivity C-
reactive protein. Our work identified new genetic deter-
minants associated with the quantitative levels of these
inflammatory biomarkers and confirmed known ones.
Overall, the data highlight an intricate regulation of this
complex biological phenomenon and reveal proteins and
mechanisms that can now be followed up with adequate
functional studies.
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10, subfamily J, member 1), and OR10J5, that have been previously
reported to be associated with MCP-1 levels (Table S1) [22].
Interestingly, when we performed a conditional analysis on the top
SNP in the DARC gene, SNP rs3026968 in the CADM3 gene still
showed a strong association (p=4.26610
208), indicating that this
marker represents an independent signal (r
2 with rs12075=0.043).
SNPs with borderline association signals with MCP-1 levels were
also found on chromosome 6p21.3, near the HLA-DRB9 (major
histocompatibility complex, class II, DR beta 9) pseudogene (rs9405112,
p=6.43610
208); on chromosome 20q13, near the CDH4 (cadherin
4) gene (rs6513566, p=5.29610
208), and on 3p21 at the 59 of the
CCR2 gene (rs3918357, p=8.49610
208), encoding the chemokine
(C-C motif) receptor 2, which acts as the MCP-1 receptor.
hsCRP
For hsCRP, the strongest association signal was observed in the
CRP (C-reactive protein) gene on chromosome 1q21-q23, confirming
previous findings [23–25]. The top marker (rs1341665,
p=2.82610
216, 0.692 mg/L average increase per G allele) is in
strong LD with several variants, including rs1205, a 3-prime
flanking region SNP previously implicated in CRP expression and
systemic lupus erythematosus susceptibility (Table 1 and Table S1)
[26]. In addition, we detected the presence of a novel independent
signal at rs3845624 downstream of the DARC gene
(p=1.43610
210,r
2=0.015 with rs1341665 and r
2=0.009 with
rs1205). Indeed, when accounting for rs1341665, several SNPs in
the DARC locus, and in particular rs3845624, still showed evidence
for association (p=4.75610
207), suggesting a role for this gene in
the regulation of CRP levels.
Step 2: Follow-Up of Initial Findings
To corroborate our initial findings, we examined with TaqMan
genotyping technology the 4 top associated SNPs (p,5610
208), as
well as 3 additional SNPs including the 2 independent signals in
the CADM3 and DARC loci (rs3026968 and rs3845624), and one
suggestive SNP with p,10
206 near HLA-DRB9 (rs9268858), in a
group of 1,392 Sardinians enrolled in the same SardiNIA study
but unrelated to the individuals analyzed in Step 1 GWAS. This
independent cohort has been previously described as SardiNIA
stage 2 [27]. Table 1 provides a summary of the follow-up results
for the SNPs with the strongest association signal at each locus as
well as a combined analysis.
Follow-up analysis of the top SNP rs643434 in ABO showed
replication of this signal in SardiNIA stage 2 (p=4.07610
205,
Table 1), supporting a role for this gene in regulating the levels of
IL-6.
For ESR, replication was observed for both the top marker in
the known CR1 gene (rs12034598, p=2.19610
204 for its
genotyped proxy rs650877 with r
2=1), and the SNP in the b-
globin LCR, (rs4910742, p=8.62610
203 for its genotyped proxy
rs10500647 with r
2=0.661) (see Table 1). As observed in the Step
1, when we repeated the association analysis for the latter SNP,
including in the model b-Thal carrier status as a covariate, the
association disappeared (p=0.34).
The top SNP in the chemokine receptor gene DARC known to
be associated with MCP-1 levels was also strongly replicated
(rs12075, p=4.93.610
225). The relatively lower association signal
showed by rs12075 in the SardiNIA discovery cohort (Step 1)
compared to the follow-up cohort SardiNIA stage 2 is most likely
due to the fact that it was imputed with a modest imputation score
in the initial GWAS, whereas it was directly genotyped in the
replication cohort. The association signal at rs3026968 in CADM3
was also confirmed in SardiNIA stage 2 (p=0.0147, Table 1),
whereas the association at rs9405112 in the HLA-DRB9 region was
not (p=0.59). Neither the signal in the CDH4 gene, or that at
rs3918357 in the CCR2 gene were followed up; however, the latter
supports a previously reported suggestive association in the CCR2/
CCR3 cytokine receptor gene cluster (rs12495098, r
2=1 with
rs3918357) [21].
Finally for hsCRP, the top SNP associated in the known CRP
gene was fully confirmed (p=1.32610
205 for its perfect proxy
rs2808628, r
2=1) (Table 1), and replication was observed also for
the independent signal at rs3845624, near DARC (p=0.027,
Table 1).
Step 3: Gene-Specific Scan using Custom Genotyping
Arrays
To refine the contribution of the detected loci and increase the
power to detect novel signals, we performed an additional
association scan by testing 293,875 variants assessed in the whole
SardiNIA cohort (6,145 individuals, including the discovery and
Table 1. Top genome-wide association results for IL-6, ESR, MCP-1, and hsCRP.
SardiNIA GWAS SardiNIA stage 2 Combined
Trait Gene Marker
Allele Minor/
Major N RSQR Freq Effect
a(SE) p-value N Freq Effect
a(SE) p-value N p-value
IL-6 ABO rs643434 A/G 4621 0.999 0.258 -0.245(0.026) 2.69610
221 1390 0.264 20.160(0.039) 4.07610
205 6011 8.68610
225
ESR CR1 rs12034598 A/G 4689 GEN 0.408 20.143(0.022) 9.31610
211 1392 0.370 20.128(0.035) 2.19610
204 6081 8.82610
214
HBB rs4910742 G/A 4689 GEN 0.066 20.229(0.042) 6.34610
208 1375 0.051 20.199(0.076) 8.62610
203 6064 1.89610
209
MCP-1 DARC rs12075 A/G 4624 0.709 0.490 0.303(0.026) 1.68610
230 1392 0.560 0.399(0.039) 4.93610
225 6016 4.33610
251
CADM3
b rs3026968 T/C 4153 GEN 0.120 0.239(0.033) 7.63610
213 1226 0.120 0.151(0.062) 1.47610
202 5379 8.70610
214
hsCRP CRP rs1341665 A/G 4434 0.963 0.417 20.195(0.024) 2.82610
216 1069 0.371 20.188(0.043) 1.32610
205 5503 1.98610
220
DARC
b rs3845624 C/A 3985 GEN 0.470 0.140(0.220) 1.43610
210 941 0.470 0.102(0.046) 2.66610
202 4926 1.65610
211
The table summarizes top genome-wide association signals for IL-6, ESR, MCP-1 and hsCRP phenotypes in the HapMap based GWAS (Step 1), as well as resultsi nt h e
replication independent cohort (Step 2) and in the combined data-sets. For each marker, frequency and effect estimates are given with respect to the minor allele.
Imputation quality scores (RSQ) are reported for imputed SNPs. Novel signals are indicated in bold.
aThe effect size is measured in standard deviation units, being estimated as the b coefficient of the regression model when using the normalized trait (e.g. an effect size
of 1.0 implies each additional copy of the allele being evaluated increases trait values by 1.0 standard deviations).
bIndependent signals.
doi:10.1371/journal.pgen.1002480.t001
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ImmunoChip [12] and the MetaboChip [13], two Illumina
custom arrays designed to follow up regions of prior interest in
immune- and metabolic-related traits and diseases, respectively, as
detailed in the Methods section. With this approach, we not only
validated with an independent genotyping method, and refined all
the association results at the previously described loci (see Figure
S1, Table 1), but also identified novel signals for all traits (Figure 1,
Table 2). A detailed view of the associated regions is illustrated in
Figure 2 and Figure 3, and results discussed below. The effect of
the associated variants on trait variability per genotype is
represented in Figure S2 and Figure S3.
IL-6
For IL-6 levels, besides corroborating the association at the ABO
gene (strongest hit rs657152, p=2.13610
229), we also observed a
signal at rs4129267 (p=2.36610
208, with an average increase of
0.220 pg/ml per T allele), in the IL-6R (IL-6 receptor) gene (Table 2,
Figure 2A and 2B, and Figure S2). This SNP is a proxy of the
functional SNP rs8192284 (r
2=0.982 in HapMap CEU) affecting
cleavage of IL-6 soluble receptor (IL-6 sR), which was previously
found associated with both IL-6 sR and IL-6 levels by admixture
mapping and candidate gene analysis in African and European
Americans [28]. SNP rs4129267 was genotyped in the Step 1
GWAS but observed with a lower p-value (p=2.45610
204).
Conditional analysis did not reveal any independent signals at
such loci. The top variants at ABO (rs657152) and IL-6R
(rs4129267) explain 2.2% of the total phenotype variation.
ESR
The scan for ESR, in addition to strong confirmatory signals in
CR1 (strongest hit rs12567990, p=8.26610
215), detected a novel
associated SNP, rs10903129, in TMEM57 (Transmembrane protein
57)(p=3.91610
208, with an average increase of 0.581 mm/h per
G allele) (Table 2, Figure 2C and 2D, and Figure S2). SNP
rs10903129 was analysed in the Step 1 GWAS, but its p-value did
not reach genome-wide significance (p=9.30610
205) and thus it
was not considered for follow-up in Step 2. Although this gene
encodes a largely uncharacterized protein, polymorphisms in the
region have been previously reported associated with lipid levels,
CHD and more recently with ESR [14,29]. We also detected a
novel signal on chromosome 12q24.31 near the UNC119B (Unc-
119 homolog B) and SPPL3 (Signal peptide peptidase-like 3) genes at a
low frequency SNP, rs11829037, with a large effect
(p=8.91610
210, MAF= 0.009, average increase of 4.657 mm/
h per the minor T allele) (Figure 2E and Table 2). It was
Figure 1. Manhattan plot and QQ plot of association findings. The figure summarizes the association results obtained on the ImmunoChip
and MetaboChip markers (Step 3). The blue dotted line marks the Bonferroni threshold significance levels (1.7610
27), and SNPs in loci exceeding this
threshold are highlighted in green. The bottom panel represents the QQ plot, where the red line corresponds to all test statistics, and the blue line to
results after excluding statistics at top markers (highlighted in green in the Manhattan Plot). The gray area corresponds to the 90% confidence region
from a null distribution of P values (generated from 100 simulations).
doi:10.1371/journal.pgen.1002480.g001
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was supported by SNPs genotyped with both arrays, and by more
common SNPs (MAF up to 0.05 for the 18 SNPs with p-
value,10
26). It is missing and not well tagged in the HapMap
data set, which provides an explanation as to why it was not
discovered in the initial scan (step 1). Finally, we confirmed the
association at rs4910742 (p=2.31610
211) in the HBB locus
(Figure 2F). Conditional analysis did not reveal any independent
signals at such loci. The top variants at CR1 (rs12567990), HBB
(rs4910742), TMEM57 (rs10903129) and UNC119B/SPPL3
(rs11829037) explain 2.3% of the total trait variation.
MCP-1
For MCP-1, the association with the coding SNP in DARC was
corroborated with a striking p-value (rs12075, p= 7.43610
2102)
(Figure 3A and Table 2). In addition, SNP rs17141006, 10 kb
upstream of its receptor CCR2, correlated with the previous
borderline signal (r
2=0.997), reached genome-wide significance
(rs17141006, p=7.53610
213, average increase per C allele was
42.14 pg/ml) (Table 2, Figure 3B and Figure S2). As mentioned
earlier, SNPs in the CCR2/CCR3 receptor cluster associated with
MCP-1 levels were previously reported by Shnabnel et al. [21],
although these associations did not reach the genome-wide
significance threshold. Our study thus refines the association and
points to CCR2 as the most likely candidate for a role in the levels
of MCP-1. We also carried out a search for independent SNPs by
conditioning on the strongest associated variant, but this analysis
did not reveal any evidence. The independent signal in CADM3 or
an adequate proxy were not included on the custom arrays, and
thus it could not be tested in this data set. However, since the SNP
was available in both the SardiNIA discovery cohort (Step 1) and
SardiNIA stage 2 data sets, genotypes were accessible for the entire
cohort and independency was confirmed. We estimated that all
together the top variants at DARC (rs12075), CCR2 (rs17141006),
and CADM3 (rs3845624) explain 9.8% of the phenotypic
variation.
hsCRP
For hsCRP, strong association signals were detected in the
previously described CRP gene (rs1205, p=8.20610
230)a n di n
the 39 of APOC-I (Apolipoprotein C-I) gene (rs4420638,
p=7.12610
211) (Figure 3C and 3D and Table 2), a well known
determinant of serum hsCRP that did not reach statistical
significance (p=2.85610
25) in our initial scan (Stage 1) [25]. A
novel and previously unknown signal with a large phenotypic
impact was identified at a rare variant, rs113459440
(p=1.54610
208, MAF=0.003, average increase of 5.35 mg/L
per T allele), near ICOSLG (Inducible T-cell co-stimulator ligand) and
the AIRE (Autoimmune regulator) genes (Figure 3E and Figure
S3). Common variants at the first gene have been associated by
GWAS with the risk of Ulcerative colitis, Celiac disease, Chron’s
disease and ankylosin spondilytis in Europeans [30–32], whereas
at the latter gene with Rheumatoid arthritis in Japanese [33]. The
AIRE gene is also responsible for Autoimmune polyendocrino-
pathy syndrome, type I (APECED), an autosomal recessive
autoimmune disease relatively common in Sardinia (OMIM #
607358). Association was supported by other SNPs genotyped
with the ImmunoChip (7 SNPs with p-value,10
26,w i t hM A F
up to 0.007). In addition, we observed that the same low
frequency SNP at UNC119B/SPPL3 associated with ESR levels
was also associated with hsCRP (rs11829037, p=1.50610
214,
average increase of 3.68 mg/L per T allele) (Figure 3F, Table 2
Table 2. Top association signals for IL-6, ESR, MCP-1, and hsCRP in the ImmunoChip and MetaboChip data-sets.
Trait Gene Marker
Allele
Minor/
Major N Freq Effect
a(SE) p-value Array
b
r
2 with GWAS
(SNP)
IL-6 ABO rs657152 T/G 5915 0.269 20.219 (0.019) 2.13610
229 I 1 (rs643434)
IL6R rs4129267 T/C 5915 0.260 0.109 (0.020) 2.36610
208 I–
ESR CR1 rs12567990 C/T 6021 0.408 20.152 (0.020) 8.26610
215 I 0.945 (rs12034598)
HBB rs4910742 G/A 6021 0.075 20.208 (0.031) 2.31610
211 I (same SNP)
TMEM57 rs10903129 G/A 6021 0.339 20.093 (0.017) 3.91610
208 I–
UNC119B/SPPL3 rs11829037 T/C 6106 0.009 0.523 (0.085) 8.91610
210 M–
MCP-1 DARC rs12075 G/A 6010 0.445 20.405 (0.019) 7.43610
2102 M (same SNP)
CCR2 rs17141006 C/T 5924 0.101 0.253 (0.035) 7.53610
213 I 0.997 (rs3918357)
hsCRP CRP rs1205 T/C 5705 0.383 20.209 (0.018) 8.20610
230 I 0.961 (rs1341665)
CRP
c,d rs3093077 G/T 5705 0.118 0.173 (0.027) 5.73610
221 I 0.043 (rs3845624)
UNC119B/SPPL3 rs11829037 T/C 5791 0.009 0.713 (0.093) 1.50610
214 M–
HNF1A
c,d rs2259816 A/C 5703 0.335 20.114 (0.019) 5.41610
206 I–
APOC-I rs4420638 G/A 5657 0.094 20.200 (0.031) 7.13610
211 I–
ISOCG/AIRE rs113459440 T/C 5704 0.003 0.819 (0.145) 1.54610
208 I–
The table summarizes top association signals for IL-6, ESR, MCP-1 and hsCRP phenotypes in the ImmunoChip and MetaboChip data-sets (Step 3). For each marker,
frequency and effect estimates are given with respect to the minor allele. We also reported the r
2 with the SNP detected in the GWAS scan (Step 1). Novel signals are
indicated in bold.
aThe effect size is measured in standard deviation units, being estimated as the b coefficient of the regression model when using the normalized trait (e.g. an effect size
of 1.0 implies each additional copy of the allele being evaluated increases trait values by 1.0 standard deviations).
bI= ImmunoChip, M= MetaboChip.
cThe table reports the pvalue on the primary analysis. On the conditional analysis, the pvalue for the independent SNPs were: rs12378220, 9.43610
208; rs3093077,
9.02610
211; rs2259816, 7.58610
210.
dIndependent signals.
doi:10.1371/journal.pgen.1002480.t002
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genuine, supported by SNPs genotyped with both arrays and
several common SNPs (MAF up to 0.38 for the 22 SNPs with p-
value,10
26). Notably, signals at SNPs within SSLP3 were
previously detected associated with CRP levels in an isolated
founder population from the Pacific Island of Kosrae, although
the p-values did not reach the genome-wide threshold [34]. None
of those SNPs was correlated to the top SNP associated in our
study; however the four SNPs which were genotyped
(rs10437838, rs6489780, rs1039302, rs10431387) showed consis-
tent direction of allele effects (increasing value for the minor
allele) as in Lowe et al., albeit with weak evidence
(0.04,p,0.09). This further indicates that association at this
locus cannot be spurious. Conditional analysis revealed the
presence of two independent signals. The first was within the CRP
gene, at SNP rs3093077 (p=9.02610
211 after conditioning for
rs1205, with average increase of 0.724 mg/L per G allele)
(Figure 3C, Table 2 and Figure S3). This marker is independent
from the signal observed 461 Kb downstream in the Step 1
GWAS scan, rs3845624, near the DARC gene (r
2=0.043).
Figure 2. Zoom views of the association results in the loci associated with IL-6 and ESR. Each panel shows the association curve around
the strongest SNP, which is highlighted with a purple dot. The SNPs are coloured according to their linkage disequilibrium (r
2) with the top variant in
the 1000 Genomes European data set, with symbols that reflect genomic annotation as indicated in the legend. Arrows highlight independent
signals, if any, described in the manuscript; while light blue lines indicate the recombination rate, according to the right-hand Y axis. Genomic
positions are as in build 37. Gene transcripts are annotated in the lower box. Plots were drawn using the standalone LocusZoom version [65].
doi:10.1371/journal.pgen.1002480.g002
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HapMap-based GWAS data set, the association signal at
rs3845624 was still significant. The second independent signal
was at rs2259816 (p=7.58610
210 after conditioning for
rs11829037, with average increase of 0.381 mg/L per C allele),
in an intron of the HNF1A (Hepatic nuclear factor-1a)g e n ea b o u t
300 Kb downstream from the UNC119B/SPPL3 locus (Figure 3F,
Table 2, and Figure S3). This marker is a perfect proxy of
rs1169310, a variant reported by a previous study [24]. The best
signal at this locus on our initial GWAS (Step 1) was at a linked
SNP, rs7953249 (r2=0.5), which did not reach genome-wide
significance level (p=7610
206). Overall the top variants at CRP
(rs1205), APOC-I (rs4420638), ICOSLG/AIRE (rs113459440),
UNC119B/SPPL3 (rs11829037), and the independent variants
at CRP (rs3093077), DARC (rs3845624) and HNF1A (rs2259816)
explain 5.6% of the phenotypic variation of this trait.
Figure 3. Zoom views of the association results in the loci associated with MCP-1 and hsCRP. Each panel shows the association curve
around the strongest SNP, which is highlighted with a purple dot. The SNPs are coloured according to their linkage disequilibrium (r
2) with the top
variant in the 1000 Genomes European data set, with symbols that reflect genomic annotation as indicated in the legend. Arrows highlight
independent signals, if any, described in the manuscript; while light blue lines indicate the recombination rate, according to the right-hand Y axis.
Genomic positions are as in build 37. Gene transcripts are annotated in the lower box. Plots were drawn using the standalone LocusZoom version
[65].
doi:10.1371/journal.pgen.1002480.g003
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Our results, besides confirming previous associations, highlight
new determinants for variation at the major inflammatory
biomarkers IL-6, ESR, MCP-1 and hsCRP.
Specifically, we found a novel highly significant association
between IL-6 expression levels and the ABO locus, with our top
associated marker tagging the O allele. This association is of
special interest, given the numerous biological effects of this
cytokine as well as the associations previously reported of the O
allele with both inflammatory traits and diseases [35–38]. In
contrast to individuals with A and B alleles, individuals with the O
blood group do not produce either the A or B antigens because of
a single-base deletion in the gene sequence, whose product
catalyzes the transfer of carbohydrates to the H antigen, forming
the antigenic structure of the ABO blood group. Our data show
that individuals carrying two copies of the G allele at our top SNP,
corresponding to blood type O carriers, display highly increased
IL-6 circulating levels compared to non-O carriers (average
increase of 1.38 pg/ml for homozygotes of the G allele, compared
to opposite homozygotes). This is consistent with the observation
that blood type O individuals show an enhanced inflammatory
response to Helicobacter pylori, with a significantly higher release of
IL-6 [39]. The detected association at the ABO locus with the IL-6
phenotype may also provide a mechanistic clue for previous
associations of the O blood group with various diseases with an
inflammatory component such as cancer and heart disease,
although determining the workings of this puzzle will likely also
require specific functional studies.
Our study also revealed novel associations with ESR levels at
the HBB and the UNC119B/SPPL3 loci. Although the impact of
the associated variants at HBB in ESR values is somewhat
expected in Sardinia because of the high frequency of carriers of b-
Thalassemia (see Results), our work indicates a direct link
supported by a genetic association. The link of UNC119B/SPPL3
with ESR is currently less clear. Interestingly, we also found that
the same UNC119B/SPPL3 variant was associated with hsCRP
levels, a finding supported by a recent study showing suggestive
evidence at SNPs within the SPPL3 gene with CRP levels variation
[34]. As expected by the strong correlation of CRP blood
circulating levels and ESR (i.e., high blood levels of acute phase
proteins increase ESR), the same allele of the associated SNP at
UNC119B/SPPL3 increases both CRP and ESR, further support-
ing that the association at this locus is genuine.
Our results highlighted a novel association at the MCP-1
receptor CCR2, with a clear involvement with MCP-1 levels,
previously only suggestively associated with this trait [21].
Confirming previous findings of Schabnel and colleagues [21],
we also found robust evidence of association between MCP-1 and
SNPs in the DARC gene, an unusual transmembrane chemokine
receptor, which binds the two main families of inflammatory
chemokines, CXC and CC (i.e., MCP-1). The top signal (rs12075)
is a non-synonymous SNP located in exon 3 of the gene, that
generates a Gly42Asp amino acid change in the DARC protein.
The predicted impact of the mutation, as well as the strength of
the association signal compared to all nearby variants, suggests
that it represents a causal variant, as previously hypothesized [21].
However and intriguingly, our results indicate that the association
in the region is complex, with one novel genome-wide significant
independent signal at the upstream gene CADM3. In addition, we
also observed that SNPs near the DARC gene are associated with
variation in CRP levels. Although the biological implications of
these SNPs on DARC function are at present unclear, this is
consistent with the observation that MCP-1 production by
endothelial cells rises in response to CRP [40]. The DARC
associations with CRP and MCP-1 were genetically independent
of each other, supporting the notion of a complex correlation
between hsCRP and MCP-1, and suggesting a multi-layered
control of expression of the inflammation response in the DARC
region.
Finally, in spite of the small sample size compared with the large
meta-analyses conducted so far [25], our study identified several
new variants associated with hsCRP levels, including an
independent signal at CRP, the signal at the previously discussed
UNC119B/SPPL3 locus and an unexpected signal at ISOCG/AIRE.
Although the SNP associated with hsCRP at the UNC119B/SPPL3
locus is independent and not correlated (r2,0.1) with the known
signal at HNF1A located about 300 kb downstream [24], at
present we cannot exclude that this SNP may act as an eQTL or
more generally in the regulation of HNF1A expression.
Interestingly, the majority of the association signals (and
specifically at IL6R, TMEM57, UNC119B/SPPL3, CCR2, APOC-
I, HNF1A, the CRP independent signal, and ICOCG/AIRE), were
observed, at least at the genome-wide level of significance, only
after genotyping the MetaboChip and ImmunoChip custom
arrays, which were typed in our cohort primarily to assess other
phenotypes. All these signals, apart from that at ICOCG/AIRE, had
supporting evidence for the involvement in the specific trait
variation from previous reports, indicating that the associations are
not spurious. The strongest variants were either not genotyped
with the commercial arrays used in our initial scan, missing or
poorly tagged in the HapMap-based reference panel we used for
imputation, or only partially genotyped (given our genotyping
strategy), resulting in inadequate power for being detected at the
required significance level in the GWAS scan. This suggests that
cost effective custom arrays could improve our understanding of
the genetics underlying trait variation even for a phenotype, such
as inflammation, for which the array was not specifically designed.
Understanding the effects of the protein products of all the
discovered loci in inflammation is an important goal, which may
also likely have clinical implications. For instance, whereas CRP
and ESR are the most widely used non-specific diagnostic markers
of inflammation, the factors and fine mechanisms regulating their
levels and interfering with them are only partially understood.
Overall, our results contribute to improve the current
knowledge of the regulation of the inflammatory response. While
inflammation is canonically thought of as involving leukocyte
migration and infiltration, the fact that several of the variants
identified are better noted in erythrocyte function may suggest a
more active role for the red cell in this process, beyond its obligate
role in ESR. Notably, four of the associated loci (ABO, HBB, DARC
and CR1) have been implicated in resistance to malaria, a disease
endemic in Sardinia until a few decades ago [41–45]. This raises
the possibility that the genetic selection imposed by malaria may
have contributed to shaping levels of inflammation, at least for
these specific inflammatory biomarkers, in this population [46].
Still, a link between these specific genes and variants with malaria
remains speculative and needs to be further assessed with adequate
biological and genetic analyses; for instance, they could be tested
and cross-compared with future statistically well powered GWAS
on Malaria and other infectious disorders.
A related potential detrimental consequence of inflammation is
that polymorphisms which have been selected because they
promote pro-inflammatory responses may increase the risk for
diseases with an inflammatory component [47,48], particularly
those that show a high frequency in Sardinia, such as Multiple
Sclerosis (MS) and Type 1 diabetes (T1D) [49,50]. However, we
could not find any evidence of association of the top SNPs
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MS cases, 1,377 T1D cases and 1,922 unrelated controls, all from
Sardinia [51], with a power of 60% and 33% to detect variants
with an odds ratio of 1.4 and MAF of 0.1 at a significance level of
1610
207, indicating that larger sample sizes are required to
identify association at variants with smaller effects or of lower
frequency (data not shown). Similarly, these variants were not
found associated to other autoimmune diseases in larger data-sets
(T1Dbase, http://t1dbase.org; and the GWAS Catalog, http://
www.genome.gov/gwastudies/).
Another possibility is that these pro-inflammatory variants play
a positive role in protection against serious diseases. For instance,
the ABO O allele is also associated with a reduced risk of
myocardial infarction and pancreatic and skin cancer [52–54].
Our results suggest that an increase in the circulating levels of IL-6
can indeed contribute to these associations involving the O group.
In conclusion, our work highlights important aspects of the
complex and multilayered regulation of inflammation and may
provide a route to understanding possible attendant effects on a
number of serious diseases.
Methods
Ethics Statement
All individuals studied and all analyses on their samples were
done according to the Declaration of Helsinki and informed
consents were approved by the local ethics committee for the
Istituto di Ricerca Genetica e Biomedica-CNR (IRGB-CNR;
Cagliari, Italy) and by MedStar Research Institute, responsible for
intramural research at the National Institutes of Aging, Baltimore,
Maryland, United States.
Sample Description
We recruited and phenotyped 6,148 individuals, males and
females, ages 14–102 y, from a cluster of four towns in the Lanusei
Valley of Sardinia [11]. During physical examination, a blood
sample was collected from each individual and divided into two
aliquots. One aliquot was used for DNA extraction and the other
to characterize several blood phenotypes, including evaluation of
serum levels of hsCRP, IL-6, MCP-1, and values of ESR.
Descriptive statistics of the study cohort are shown in Table S2.
Serum levels of hsCRP were measured by the high sensitivity
Vermont assay (University of Vermont, Burlington), an enzyme-
linked immunosorbent assay calibrated with WHO Reference
Material [55]. The lower detection limit of this assay is 0.007 mg/
l, with an inter-assay coefficient of variation of 5.14%. Serum
levels of IL-6 and MCP-1 were measured by Quantikine High
Sensitive Human Immunoassays (R&D Systems, Inc.), according
to manufacturer’s instructions. This method employs solid-phase
ELISA techniques. For IL-6, the lower detection limit is 0.039 pg/
ml. The intra-assay coefficient of variations (CVs) were 6.9% to
7.8% over the range 0.43–5.53 pg/ml. For MCP-1, the lower
detection limit is 5.0 pg/ml. The intra-assay coefficient of
variations (CVs) were 4.7% to 7.8% over the range 76.7–
1121 pg/ml. ESR was measured using sedimentation measure-
ment tubes buffered with 3.8% sodium citrate (Venoject-Terumo).
After mixing of 2.4 ml of blood with the additive, tubes were left in
a vertical position in the specific support with graduation markings
for 30 minutes to allow sedimentation of the erythrocytes by
gravity. The erythrocyte sedimentation rate is calculated in
Westergreen units (mm/h) determining the length at the
plasma/erythrocyte cell interface level within the sedimentation
tube. Samples affected by multiple sclerosis (MS) and type 1
diabetes (T1D) used for the side case-control analysis briefly
reported in the Discussion were recruited from all the island as
previously described (51). Only 20 of these samples overlapped
with those in the SardiNIA cohort.
GWAS Genotyping and Statistical Analysis
During the study, we genotyped 4,694 individuals selected from
the whole sample to represent the largest available families,
regardless of their phenotypic values. Specifically, 1,412 were
genotyped with the 500 K Affymetrix Mapping Array set, 3,329
with the 10 K Mapping Array set, with 436 individuals genotyped
with both arrays. We also recently typed 1,097 individuals with the
Affymetrix 6.0 chip, of which 1,004 and 66 were also typed with
the 10 K and 500 K chips respectively. This genotyping strategy
allowed us to examine the majority of our cohort in a cost-effective
manner since genotypes for the SNPs that passed quality control
checks could be propagated through the pedigree using imputa-
tion. Measurements of inflammatory biomarkers were available for
4,137, 4,292, 4,295 and 3,596 individuals for hsCRP, IL-6, MCP-
1 and ESR, respectively, among the 4,694 genotyped. A total of
731,209 autosomal SNPs passed stringent quality control checks.
Quality checks for the 10 K and 500 K chips were described
previously [56]. For the Affymetrix 6.0 chip, similar criteria were
used, as detailed in Table S3. In addition, we also removed SNPs
in common between the other chips that showed an high level of
discordance or that generated too many discrepancies when
comparing genotypes across 11 duplicates. After performing
quality control checks and merging genotypes from the three
gene chip platforms, we used the quality controlled 731,209
autosomal markers to estimate genotypes for all polymorphic
SNPs in the CEU HapMap population (release 22) [57], in the
individuals genotyped with the 500 K Array and the 6.0
Affymetrix chip separately using the MaCH software [58]. Taking
advantage of the relatedness among individuals in the SardiNIA
sample, we carried out a second round of computational analysis
to impute genotypes at all SNPs in the individuals who were
genotyped only with the Affymetrix Mapping 10 K Array, being
mostly offspring and siblings of the individuals genotyped at high
density. At this second round of imputation, we focused on the
SNPs for which the imputation procedure predicted r
2.0.30
between true and imputed genotypes and for which the inferred
genotype did not generate an excess of Mendelian errors. We then
used a modified version of the Lander-Green algorithm, as
previously described [3,56] to estimate IBD sharing at the location
of the SNPs being tested and identify stretches of haplotype shared
with close relatives who were genotyped at higher density and
probabilistically infer missing genotypes. The within-family
imputation procedure and the association test are implemented
in Merlin software [59,60]. Due to computational constraints, we
divided large pedigrees into sub-units with ‘‘bit-complexity’’ of 21
or less (typically, 25–30 individuals) before analysis.
For association, we evaluated the additive effect of genotyped
and imputed SNPs on inflammatory biomarker levels using a
family-based association test implemented in Merlin (–fastassoc
option) [59,60]. This test accounts for relatedness under the
assumption that the samples analyzed are from an ethnically
homogeneous population [59,60], and this is suggested by
demographic records indicating that 89% of the participants were
born in the same 31 Km
2 area and for 95% of the volunteers, both
parents and all grandparents were born in Sardinia [11]. At each
SNP, levels of each biomarker of inflammation were regressed
onto allele counts in a regression model that included gender, age,
and age-squared as covariates. We also used a second model,
which included body-mass index (BMI) and smoking status as
additional covariates, as these have been previously implicated as
Regulatory Variants of Inflammation
PLoS Genetics | www.plosgenetics.org 9 January 2012 | Volume 8 | Issue 1 | e1002480being associated with inflammatory biomarker levels [24]. Here
we report the results from the second model, where the inclusion
of the additional covariates improved the variance explained by
the model (from 1.8% to 3.7% for CRP, from 18.1% to 19.5% for
ESR, from 6.8% to 7.6% for IL-6, and from 3% to 3.3% for
MCP-1). Genomic control parameters show negligible inflation
(1.049, 1.039, 1.031 and 1.115, respectively for hsCRP, MCP-1,
IL-6 and ESR); nevertheless the corresponding correction factors
were applied to the GWAS results to completely avoid spurious
associations.
Follow-Up Sample
The SardiNIA stage 2 cohort was used to follow-up initial
findings [27]. Genotyping of specific SNPs was performed in
Sardinian individuals selected for replication efforts using TaqMan
single SNP genotyping assays (Applied Biosystems). In particular,
we genotyped and analysed 1,392 individuals from the SardiNIA
stage 2 cohort, who were unrelated (kinship coefficient=0) to the
individuals analysed in the GWAS.
ImmunoChip and MetaboChip: Genotyping and
Statistical Analysis
We successfully genotyped 6,145 samples using the MetaboChip
and ImmunoChip arrays (Illumina). The MetaboChip was
designed in collaboration with several international consortia
[3,61,62] with the aim to fine map association loci detected
through GWAS for a variety of traits. Part of the design included a
set of wild-card SNPs chosen by individual research groups; the
SardiNIA study promoted several SNPs associated with a wide
range of traits, including rs12075. The ImmunoChip is also a
consortium based array, designed to fine map loci associated to 12
immunologically related human diseases, or immune-mediated
disease loci, as well as a set of wild-card SNPs. The SardiNIA
study had not role in the design of this array, and a full detailed
description is provided elsewhere [12]. All samples had a
genotyping call rate .98%, and SNP genotypes were carefully
assessed though several quality control checks. In particular, we
removed markers with call rate ,98%, with strong deviation from
HWE (p,10
26), that were monomorphic or leading to an excess
of Mendelian errors (defined as .1% of the families). A detailed
breakdown of markers excluded by each filter criteria is provided
on Table S4. Since the majority of the variants included on these
custom arrays are of low frequency compared to the GWAS data
set (average MAF= 0.176, compared to 0.219 observed in
GWAS), the impact of hidden population structure and imprecise
modelling of relatedness due to pedigree splitting (task we
performed on the GWAS data set due to computational
constraints) could be problematic. Analysis was thus carried out
using EMMAX, a variant component model that overcomes such
issues by using a genomic-based kinship matrix [63]. To calculate
the kinship matrix, we used all SNPs that passed quality control
checks but excluding those with MAF between 0 and 1%.
Association analysis was subsequently performed testing all QCed
SNPs (Table S4), in spite of their minor allele frequency. Observed
genomic lambda were 1.01, 0.962, 1.00 and 1.01, respectively for
IL6, VES, MCP1, and hsCRP (as a note, genomic lambda using
Merlin on the same data set were 1.41, 1, 1.26 and 1.14,
respectively). To declare an association significant, we used a
Bonferroni threshold of 0.05/293,875=1.7610
27.
Variance Explained
The variance explained by the strongest associated SNPs was
calculated, for each trait, as the difference of R2 adjusted observed
in the full and the basic models, where the full model contains all
the independent SNPs in addition to the covariates.
Conditional Analysis
We performed conditional analysis at each locus by adding the
top associated SNP to the already included covariates, and testing
for association the remaining SNPs at the locus. A marker was
declared independent only if the p-value observed in the
conditional analysis reached genome-wide significance threshold
(5610
208 in the Step1 GWAS, and 1.7610
207 in the custom-
array based dataset) [64].
Supporting Information
Figure S1 Manhattan plot and QQ plot of association findings
in step 1 GWAS. The figure summarizes the genome-wide
association scan results combined across the data-sets by inverse
variance weighting. The blue dotted line marks the threshold for
genome-wide significance (5610
208) [64]. SNPs in loci exceeding
this threshold are highlighted in green. The bottom panel
represents the QQ plot, where the red line corresponds to all
test statistics, and the blue line to results after excluding statistics at
top markers (highlighted in green in the Manhattan Plot). The
gray area corresponds to the 90% confidence region from a null
distribution of P values (generated from 100 simulations).
(PNG)
Figure S2 Boxplots for levels of IL-6, ESR, and MCP-1 for each
genotype at the top associated SNPs. Standard boxplots are drawn
with min, 0.25 quantile; median, 0.75 quantile; and 0.75 quantile+
1.5*IQR for the levels of unadjusted biomarkers IL-6 (pg/ml),
ESR (mm/h), and MCP-1 (pg/ml) in the original units. For each
boxplot the name of the biomarker and the associated SNP are
indicated, as well as the number of individuals per genotype.
(PNG)
Figure S3 Boxplots for levels of hsCRP for each genotype at the
top associated SNPs. Standard boxplots are drawn with min, 0.25
quantile; median, 0.75 quantile; and 0.75 quantile+ 1.5*IQR for
the levels of unadjusted hs-CRP (mg/ml) biomarker in the original
units. For each boxplot the name of the biomarker and the
associated SNP are indicated, as well as the number of individuals
per genotype.
(PNG)
Table S1 Association results for SNPs with p-value,10
25 for
inflammatory biomarkers in the step 1 GWAS. The table
summarizes the association results at SNPs with p-value,10
25
for each inflammatory biomarkers. The effect size is measured in
standard deviations (e.g. an effect size of 1.0 implies each
additional copy of the allele being evaluated increases trait values
by 1.0 standard deviations) and it refers to allele 1. The r
2 between
each imputed genotype and the true underlying genotype is
provided (RSQ) and serves as a quality-control metric. The
percentage of the variance explained by each markers is also
reported (H2), and the column ‘‘I/G’’ indicates whether the SNP
has been imputed or genotyped. Physical positions are given
according to build 36. SNPs above genome-wide threshold
(p,5610
28) are indicated in bold. EA, effect allele; OA, other
allele.
(DOC)
Table S2 Descriptive statistics for the SardiNIA cohort. The
table shows the basic clinical characteristics of the SardiNIA
samples.
(DOCX)
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imputation.
(DOCX)
Table S4 Quality Controls for the MetaboChip and Immuno-
Chip data-sets. The table shows the breakdown of each criteria
applied and the relative number of markers removed. The same
marker could have failed one or more criteria. a excess was
defined as .1% of the families. b SNPs on chromosomes X and Y
were discarded for the analysis with EMMAX.
(DOCX)
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